Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
| Revenue (TTM) | $45.20B |
| Gross Profit (TTM) | $18.50B |
| EBITDA | $11.30B |
| Operating Margin | 17.90% |
| Return on Equity | 13.50% |
| Return on Assets | 5.00% |
| Revenue/Share (TTM) | $120.36 |
| Book Value | $139.75 |
| Price-to-Book | 3.70 |
| Price-to-Sales (TTM) | 4.19 |
| EV/Revenue | 5.14 |
| EV/EBITDA | 19.85 |
| Quarterly Earnings Growth (YoY) | 11.30% |
| Quarterly Revenue Growth (YoY) | 6.20% |
| Shares Outstanding | $371.62M |
| Float | $370.67M |
| % Insiders | 0.15% |
| % Institutions | 93.98% |
Volatility is currently contracting
Thermo Fisher Scientific Inc. is down 12.2% YTD, underperforming both the S&P 500 and the healthcare sector. Key risks include NIH funding uncertainty, China weakness, slow organic recovery, and integration risk from the $8.9B Clario acquisition. TMO trades at an 18% discount to its 5-year average P/E, reflecting much of the downside already priced in.
SAN FRANCISCO--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that the Applied Biosystems™ RapidINTEL™ Plus Cartridge has received approval from the Federal Bureau of Investigation (FBI) National DNA Index System (NDIS) for use with qualifying forensic crime scene samples. The law enforcement milestone makes Thermo Fisher's Rapid DNA workflow on the RapidHIT ID™ System the first eligible to generate DNA profiles that can be searched against the n.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2026 before the market opens on Thursday, July 23, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the “Investors” section of our website, www.thermofish.
genedrive PLC (AIM:GDR, FRA:D6M) has signed a collaboration agreement with Thermo Fisher Scientific, sending its shares up 8% to 1.4p. The point-of-care pharmacogenetic testing company will develop a high-throughput laboratory test under the deal.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase new capabilities, strategic investments and initiatives at BIO International 2026 that are helping pharma and biotech customers advance innovation, simplify complex workflows and bring therapies to patients faster. Spanning AI-enabled research, clinical development and advanced manufacturing, these investments reinforce Thermo Fisher's role as a trusted strategic provider of integrated.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today expanded its suite of Thermo Scientific™ Orbitrap™ mass spectrometry platforms, AI-enabled software and integrated workflows at the American Society for Mass Spectrometry (ASMS) Conference. Across research, biopharma and applied testing, scientists face increasingly complex samples, expanding data sets and greater pressure to deliver confident answers faster. Thermo Fisher helps solve that.
Thermo Fisher (TMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the Thermo Scientific™ Orbitrap™ Tribrid™ Apex and Thermo Scientific™ Orbitrap™ Excedion™ mass spectrometers will be showcased at the American Society for Mass Spectrometry (ASMS) Conference. As scientific discovery expands into more complex applications—from advanced proteomics and multiomics to biologics and genetic medicines—researchers and drug developers face inc.
Thermo Fisher Scientific Inc. (TMO) Analyst/Investor Day Transcript
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its Investor Day today. Chairman and Chief Executive Officer Marc N. Casper and members of the senior leadership team highlighted the company's industry leadership and the essential role of its best-in-class products and services to customers around the world. "Our customers value Thermo Fisher as their trusted partner,” said Marc N. Casper, chairman and chief executive office.
